Literature DB >> 18815198

Mitochondrial ferritin limits oxidative damage regulating mitochondrial iron availability: hypothesis for a protective role in Friedreich ataxia.

Alessandro Campanella1, Elisabetta Rovelli, Paolo Santambrogio, Anna Cozzi, Franco Taroni, Sonia Levi.   

Abstract

Mitochondrial ferritin (FtMt) is a nuclear-encoded iron-sequestering protein that specifically localizes in mitochondria. In mice it is highly expressed in cells characterized by high-energy consumption, while is undetectable in iron storage tissues like liver and spleen. FtMt expression in mammalian cells was shown to cause a shift of iron from cytosol to mitochondria, and in yeast it rescued the defects associated with frataxin deficiency. To study the role of FtMt in oxidative damage, we analyzed the effect of its expression in HeLa cells after incubation with H(2)O(2) and Antimycin A, and after a long-term growth in glucose-free media that enhances mitochondrial respiratory activity. FtMt reduced the level of reactive oxygen species (ROS), increased the level of adenosine 5'triphosphate and the activity of mitochondrial Fe-S enzymes, and had a positive effect on cell viability. Furthermore, FtMt expression reduces the size of cytosolic and mitochondrial labile iron pools. In cells grown in glucose-free media, FtMt level was reduced owing to faster degradation rate, however it still protected the activity of mitochondrial Fe-S enzymes without affecting the cytosolic iron status. In addition, FtMt expression in fibroblasts from Friedreich ataxia (FRDA) patients prevented the formation of ROS and partially rescued the impaired activity of mitochondrial Fe-S enzymes, caused by frataxin deficiency. These results indicate that the primary function of FtMt involves the control of ROS formation through the regulation of mitochondrial iron availability. They are consistent with the expression pattern of FtMt observed in mouse tissues, suggesting a FtMt protective role in cells characterized by defective iron homeostasis and respiration, such as in FRDA.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18815198      PMCID: PMC3298861          DOI: 10.1093/hmg/ddn308

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  53 in total

Review 1.  Antioxidant defence mechanisms: from the beginning to the end (of the beginning).

Authors:  B Halliwell
Journal:  Free Radic Res       Date:  1999-10

2.  Overexpression of mitochondrial ferritin causes cytosolic iron depletion and changes cellular iron homeostasis.

Authors:  Guangjun Nie; Alex D Sheftel; Sangwon F Kim; Prem Ponka
Journal:  Blood       Date:  2004-11-02       Impact factor: 22.113

3.  Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells.

Authors:  Hava Glickstein; Rinat Ben El; Maya Shvartsman; Z Ioav Cabantchik
Journal:  Blood       Date:  2005-07-14       Impact factor: 22.113

4.  Targeted disruption of hepatic frataxin expression causes impaired mitochondrial function, decreased life span and tumor growth in mice.

Authors:  René Thierbach; Tim J Schulz; Frank Isken; Anja Voigt; Brun Mietzner; Gunnar Drewes; Jürgen-Christoph von Kleist-Retzow; Rudolf J Wiesner; Mark A Magnuson; Hélène Puccio; Andreas F H Pfeiffer; Pablo Steinberg; Michael Ristow
Journal:  Hum Mol Genet       Date:  2005-11-08       Impact factor: 6.150

5.  Characterization of mitochondrial ferritin in Drosophila.

Authors:  Fanis Missirlis; Sara Holmberg; Teodora Georgieva; Boris C Dunkov; Tracey A Rouault; John H Law
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-29       Impact factor: 11.205

Review 6.  Iron trafficking in the mitochondrion: novel pathways revealed by disease.

Authors:  Ian Napier; Prem Ponka; Des R Richardson
Journal:  Blood       Date:  2004-11-04       Impact factor: 22.113

7.  Frataxin deficiency alters heme pathway transcripts and decreases mitochondrial heme metabolites in mammalian cells.

Authors:  Robert A Schoenfeld; Eleonora Napoli; Alice Wong; Shan Zhan; Laurence Reutenauer; Dexter Morin; Alan R Buckpitt; Franco Taroni; Bo Lonnerdal; Michael Ristow; Hélène Puccio; Gino A Cortopassi
Journal:  Hum Mol Genet       Date:  2005-10-20       Impact factor: 6.150

8.  Iron(II) and hydrogen peroxide detoxification by human H-chain ferritin. An EPR spin-trapping study.

Authors:  Guanghua Zhao; Paolo Arosio; N Dennis Chasteen
Journal:  Biochemistry       Date:  2006-03-14       Impact factor: 3.162

9.  Unique iron binding and oxidation properties of human mitochondrial ferritin: a comparative analysis with Human H-chain ferritin.

Authors:  Fadi Bou-Abdallah; Paolo Santambrogio; Sonia Levi; Paolo Arosio; N Dennis Chasteen
Journal:  J Mol Biol       Date:  2005-04-01       Impact factor: 5.469

10.  Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome.

Authors:  M G Della Porta; L Malcovati; R Invernizzi; E Travaglino; C Pascutto; M Maffioli; A Gallì; S Boggi; D Pietra; L Vanelli; C Marseglia; S Levi; P Arosio; M Lazzarino; M Cazzola
Journal:  Leukemia       Date:  2006-04       Impact factor: 11.528

View more
  60 in total

Review 1.  The emerging role of iron dyshomeostasis in the mitochondrial decay of aging.

Authors:  Jinze Xu; Emanuele Marzetti; Arnold Y Seo; Jae-Sung Kim; Tomas A Prolla; Christiaan Leeuwenburgh
Journal:  Mech Ageing Dev       Date:  2010-04-29       Impact factor: 5.432

2.  Alpha-lipoic acid and frataxin: a new indication for an old antioxidant?

Authors:  James W Russell
Journal:  Exp Neurol       Date:  2009-04-15       Impact factor: 5.330

Review 3.  Friedreich's ataxia: pathology, pathogenesis, and molecular genetics.

Authors:  Arnulf H Koeppen
Journal:  J Neurol Sci       Date:  2011-04-15       Impact factor: 3.181

Review 4.  Iron metabolism in erythroid cells and patients with congenital sideroblastic anemia.

Authors:  Kazumichi Furuyama; Kiriko Kaneko
Journal:  Int J Hematol       Date:  2017-11-14       Impact factor: 2.490

5.  Glutaredoxin 5 deficiency causes sideroblastic anemia by specifically impairing heme biosynthesis and depleting cytosolic iron in human erythroblasts.

Authors:  Hong Ye; Suh Young Jeong; Manik C Ghosh; Gennadiy Kovtunovych; Laura Silvestri; Danilo Ortillo; Naoya Uchida; John Tisdale; Clara Camaschella; Tracey A Rouault
Journal:  J Clin Invest       Date:  2010-04-01       Impact factor: 14.808

6.  Over-expression of mitochondrial ferritin affects the JAK2/STAT5 pathway in K562 cells and causes mitochondrial iron accumulation.

Authors:  Paolo Santambrogio; Benedetta Gaia Erba; Alessandro Campanella; Anna Cozzi; Vincenza Causarano; Laura Cremonesi; Anna Gallì; Matteo Giovanni Della Porta; Rosangela Invernizzi; Sonia Levi
Journal:  Haematologica       Date:  2011-06-28       Impact factor: 9.941

Review 7.  Pathological Roles of Iron in Cardiovascular Disease.

Authors:  Motoi Kobayashi; Tomohiro Suhara; Yuichi Baba; Nicholas K Kawasaki; Jason K Higa; Takashi Matsui
Journal:  Curr Drug Targets       Date:  2018       Impact factor: 3.465

8.  Increasing expression of H- or L-ferritin protects cortical astrocytes from hemin toxicity.

Authors:  Zhi Li; Jing Chen-Roetling; Raymond F Regan
Journal:  Free Radic Res       Date:  2009-06

Review 9.  Iron-sulfur cluster synthesis, iron homeostasis and oxidative stress in Friedreich ataxia.

Authors:  Rachael A Vaubel; Grazia Isaya
Journal:  Mol Cell Neurosci       Date:  2012-08-11       Impact factor: 4.314

10.  Mitochondrial ferritin in the substantia nigra in restless legs syndrome.

Authors:  Amanda M Snyder; XinSheng Wang; Stephanie M Patton; Paolo Arosio; Sonia Levi; Christopher J Earley; Richard P Allen; James R Connor
Journal:  J Neuropathol Exp Neurol       Date:  2009-11       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.